Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu
Integration of multi-source data helps to obtain more scientifically reliable results on budget impacts. The study found that the budgetary impacts of high-priced OMPs on society and payers are relatively limited. Health policymakers can choose appropriate reimbursement strategies based on financial affordability among a diverse mix of elements. The results of related studies provided insights for optimizing the allocation of health resources and improving patient access to medications.
Authors
- Yili Yang (ORCID: https://orcid.org/0000-0002-9115-6515)
- Doudou Zhang (ORCID: https://orcid.org/0000-0001-8784-5599)
- Jay Pan (ORCID: https://orcid.org/0000-0001-9501-1535)
- Xiaoxing Zhang (ORCID: https://orcid.org/0000-0001-7292-7014)
- Tingting Zhou (ORCID: https://orcid.org/0009-0008-4354-1399)
- Jing Zhou (ORCID: https://orcid.org/0000-0003-2501-0080)
Institutions
- Sichuan University (CN)
- West China Second University Hospital of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12913-024-11632-6
- Citations
- 4
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 4.52
Funders
- Bill and Melinda Gates Foundation
- National Natural Science Foundation of China
- Sichuan University
- National Office for Philosophy and Social Sciences